CDK4 and breast cancer: Interestingly, no effect of specific antitumor therapies was observed, as reported in a recent comprehensive analysis of thrombosis associated with breast cancer, where anthracyclines, platinum-based therapies, hormonal treatments like tamoxifen, and targeted therapies including CDK4/6 inhibitors were linked to an increased risk of VTE [15].